{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/croup/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"770a8563-687d-5b41-9629-8cdcd49a750a","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 6658cbfc-4d9b-4df6-9394-c7ce02e8a93f --><h2>Changes</h2><!-- end field 6658cbfc-4d9b-4df6-9394-c7ce02e8a93f -->","summary":null,"htmlStringContent":"<!-- begin item 1133072b-e7c5-41eb-b8c6-47153ca86c66 --><!-- begin field 853a297a-e931-4697-805b-ec4fd869fc00 --><p><strong>February 2019</strong> — minor update. Tachycardia has been added as a sign of impending respiratory failure. High fever and 'toxic' appearance have been added as considerations for hospital admission. </p><p><strong>April to May 2017 </strong>— reviewed. A literature search was conducted in April 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field 853a297a-e931-4697-805b-ec4fd869fc00 --><!-- end item 1133072b-e7c5-41eb-b8c6-47153ca86c66 -->","topic":{"id":"ce03d247-afbe-5290-832f-8f95361dd16e","topicId":"663c3878-b65e-49df-b738-7711612b31ed","topicName":"Croup","slug":"croup","lastRevised":"Last revised in February 2019","chapters":[{"id":"147ea703-8a02-5151-abf9-289eb232d7f7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b4d7d104-fefd-5285-8bf6-a20db31a3a6c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9b0196f5-c62f-557e-8c0b-8d5cdc4726b8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"770a8563-687d-5b41-9629-8cdcd49a750a","slug":"changes","fullItemName":"Changes"},{"id":"10a53caf-873e-57a4-880d-aefdd5a5fb65","slug":"update","fullItemName":"Update"}]},{"id":"bf5dbb8f-554f-56b2-b8ce-62573dd2d938","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7d9ae47b-5ea9-557f-b53a-5bb9f9b69fcb","slug":"goals","fullItemName":"Goals"},{"id":"a5f272bf-bd65-5548-a253-2eece07472f4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b1168d32-0a16-5a45-844c-2f9e792cfccc","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"41533497-a783-5f26-98e4-554a82823d80","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"34edf552-026f-5c4d-b4ae-95034786ca88","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ba739830-6b73-555a-9c5f-3bf3e5ec3743","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0b7a2081-6723-53ae-9566-0481028ad175","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"467402a7-bf22-5f5b-8ad9-090c0b1b6be5","slug":"definition","fullItemName":"Definition"},{"id":"93d4df12-d240-53a9-bbc6-ad12f8363460","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0128d0fb-1a94-57dd-b210-2b011720efa2","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"0fa5d183-650e-5e12-a927-5e0bcff458bd","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"90baebc8-47bc-5144-a5ac-07ace34fe1d7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b1189f4d-058a-54f6-83c8-43ed93b0d1ab","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"6c26580b-53cc-5db0-838c-71e5841fe898","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"efe34746-d360-5ce2-bdc6-4aab25a98130","fullItemName":"Management","slug":"management","subChapters":[{"id":"3020718f-b53d-5af1-89e6-5a92a4c59075","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"86c15ba0-c5cc-5a85-8d4c-490305d1540f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"76c755b1-a126-5291-8ae0-44276cfd3747","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"742b7beb-da22-597a-9bf5-35f9a3b8ff50","slug":"paracetamol-ibuprofen","fullItemName":"Paracetamol and ibuprofen"}]},{"id":"7ea6cbf9-fc01-56dd-8c9d-9b9cc1a69282","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c93aeb25-1189-5e59-bec3-5210121ed220","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f0d23dbb-0a01-5d60-9e6f-17bbf65083b3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"be9ee413-fa04-55ba-88df-d9606ca98a64","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d2337c68-6aec-522d-a1c5-329947299478","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"982ad0fa-2b63-5ea4-b6a3-200dca208aaa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"86f92b32-a806-57d4-a00e-be2a234bfdee","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7b0c8a60-9bbe-5830-8e82-d9e6b1567c0b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9b0196f5-c62f-557e-8c0b-8d5cdc4726b8","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"824ee0f4-3633-5338-bcad-3c5ad3e0bb35","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field f9c4d217-0f9b-4628-9ddb-2156c5827ddd --><h3>Previous changes</h3><!-- end field f9c4d217-0f9b-4628-9ddb-2156c5827ddd -->","summary":null,"htmlStringContent":"<!-- begin item 7445b92f-6e70-4151-981e-5f4018af95ee --><!-- begin field ecbf52aa-e606-4102-b8c1-6ffe1cf939d6 --><p><strong>September 2012 </strong>— reviewed. A literature search was conducted in September 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No changes to clinical recommendations have been made.</p><p><strong>July 2011 </strong>— minor update. More exact paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency. Prescriptions have been updated to reflect the revised dosing. Issued in July 2011.</p><p><strong>June to September 2008 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field ecbf52aa-e606-4102-b8c1-6ffe1cf939d6 --><!-- end item 7445b92f-6e70-4151-981e-5f4018af95ee -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}